📊 RLMD Key Takeaways
Is Relmada Therapeutics, Inc.. (RLMD) a Good Investment?
Relmada is a pre-profitability biotech company with unsustainable cash burn of $197.1M annually against only $9.8M cash, despite strong 93.7% YoY revenue growth. While the balance sheet shows strength with minimal debt and high liquidity, the company lacks a clear path to profitability with negative gross margins and operating margins exceeding -370%, making near-term financial viability questionable.
Relmada shows severe and persistent unprofitability with near-zero gross margin, deeply negative operating income, and heavy cash burn despite headline revenue growth. With minimal cash relative to burn and no debt capacity to lean on, fundamentals point to financing/dilution risk unless margins and operating efficiency improve materially.
Relmada Therapeutics, Inc.. Key Strengths (RLMD)
- Revenue growth of 93.7% YoY demonstrates market traction and demand
- Fortress balance sheet with zero long-term debt and $218.7M stockholders equity
- High liquidity ratios (18.26x current ratio) providing financial flexibility
- Improving diluted EPS by 45.3% YoY shows operational efficiency gains despite losses
- Large asset base of $235.4M supporting R&D and development activities
- Debt-free capital structure (0.00x D/E)
- High reported liquidity (Current/Quick >14x)
- Revenue up 93.7% YoY (albeit small base)
RLMD Stock Risks: Relmada Therapeutics, Inc.. Investment Risks
- Catastrophic cash burn of $197.1M annually is unsustainable with only $9.8M cash reserves
- Gross margin of 0.1% indicates severe pricing or cost structure issues preventing profitability
- Operating margin of -377.8% and net margin of -369.8% demonstrate spending far exceeds revenue generation
- Negative ROE (-8.7%) and ROA (-8.1%) destroy shareholder value at current trajectory
- Heavy capital expenditure of $182.1M suggests major investments with execution risk
- Sustained large operating losses and -1100%+ margins
- Severely negative free cash flow and limited cash runway
- Gross margin ~0%, raising concerns about revenue quality/sustainability
Key Metrics to Watch
- Operating cash flow trend - must improve from -$15.1M to reach sustainability
- Gross margin expansion - critical to achieving profitability as revenue scales
- Cash runway - monitor remaining months of operations before next financing round required
- Revenue per employee and operating efficiency metrics - track progress toward breakeven
- Capital allocation of $182.1M capex - validate that investments deliver future revenue growth
- Operating cash flow (burn rate)
- Cash and equivalents (including short-term investments)
Relmada Therapeutics, Inc.. (RLMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 18.26x current ratio provides a solid financial cushion.
RLMD Profit Margin, ROE & Profitability Analysis
RLMD vs Healthcare Sector: How Relmada Therapeutics, Inc.. Compares
How Relmada Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Relmada Therapeutics, Inc.. Stock Overvalued? RLMD Valuation Analysis 2026
Based on fundamental analysis, Relmada Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Relmada Therapeutics, Inc.. Balance Sheet: RLMD Debt, Cash & Liquidity
RLMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Relmada Therapeutics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.65 indicates the company is currently unprofitable.
RLMD Revenue Growth, EPS Growth & YoY Performance
RLMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2014 | $682 | -$13.2K | N/A |
| Q1 2014 | $1.9K | -$9.0K | N/A |
| Q3 2013 | $400 | -$3.4K | N/A |
| Q2 2013 | $2.3K | -$942 | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Relmada Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
RLMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Relmada Therapeutics, Inc.. (CIK: 0001553643)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RLMD
What is the AI rating for RLMD?
Relmada Therapeutics, Inc.. (RLMD) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RLMD's key strengths?
Claude: Revenue growth of 93.7% YoY demonstrates market traction and demand. Fortress balance sheet with zero long-term debt and $218.7M stockholders equity. ChatGPT: Debt-free capital structure (0.00x D/E). High reported liquidity (Current/Quick >14x).
What are the risks of investing in RLMD?
Claude: Catastrophic cash burn of $197.1M annually is unsustainable with only $9.8M cash reserves. Gross margin of 0.1% indicates severe pricing or cost structure issues preventing profitability. ChatGPT: Sustained large operating losses and -1100%+ margins. Severely negative free cash flow and limited cash runway.
What is RLMD's revenue and growth?
Relmada Therapeutics, Inc.. reported revenue of $5.2M.
Does RLMD pay dividends?
Relmada Therapeutics, Inc.. does not currently pay dividends.
Where can I find RLMD SEC filings?
Official SEC filings for Relmada Therapeutics, Inc.. (CIK: 0001553643) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RLMD's EPS?
Relmada Therapeutics, Inc.. has a diluted EPS of $-0.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RLMD's fundamental grade?
Based on our AI fundamental analysis in May 2026, Relmada Therapeutics, Inc.. has a C grade with 70% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RLMD stock overvalued or undervalued?
Valuation metrics for RLMD: ROE of -8.7% (sector avg: 15%), net margin of -369.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RLMD's AI grade for 2026?
Our dual AI analysis gives Relmada Therapeutics, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RLMD's free cash flow?
Relmada Therapeutics, Inc..'s operating cash flow is $-15.1M, with capital expenditures of $182.1M. FCF margin is -3,826.3%.
How does RLMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -369.8% (avg: 12%), ROE -8.7% (avg: 15%), current ratio 18.26 (avg: 2).